Several other studies identified various somatic ERBB3 mutations in 4% of breast cancer [119], 10% of gastric [120], 1% of ovarian [121, 122], 1% of colon cancer [117], 1% of glioblastoma [123]; 0.5% of squamous carcinomas, and 1% of head and neck cancer [124]. This evidence concerns the gene ERBB3 and malignant colon neoplasm.